V. Vendrely

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2010 · 747 citations

Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2012 · 421 citations · Full text

Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial

Éric Rullier, Philippe Rouanet, Jean‐Jacques Tuech et al. · The Lancet · 2017 · 366 citations

Gastrointestinal Oncology, Greccar 2, Colorectal Surgery +8

Sphincter-Saving Resection for All Rectal Carcinomas

Éric Rullier, F. Bretagnol, Anne Rullier et al. · Annals of Surgery · 2005 · 363 citations · Full text